CZECANCA consortium
Assertion criteria
Level: Assertion criteria not provided
Summary of submissions to ClinVar
Total submissions: 251
Gene
Gene | Submissions | Last Updated |
---|---|---|
ATM | 15 | Feb 21, 2023 |
BARD1 | 5 | Feb 21, 2023 |
BRCA1 | 62 | Feb 21, 2023 |
BRCA2 | 60 | Feb 21, 2023 |
BRIP1 | 11 | Feb 21, 2023 |
C11orf65 | 10 | Feb 21, 2023 |
CHEK2 | 15 | Feb 21, 2023 |
DCTN5 | 1 | Jun 13, 2019 |
ERCC4 | 1 | May 11, 2021 |
FANCE | 1 | May 11, 2021 |
FANCG | 1 | May 11, 2021 |
FH | 1 | Sep 1, 2022 |
HOXB13 | 1 | May 11, 2021 |
LOC126862571 | 11 | May 11, 2021 |
LOC129390903 | 1 | Jun 13, 2019 |
MLH1 | 9 | Feb 21, 2023 |
MSH2 | 7 | Feb 21, 2023 |
MSH6 | 14 | Feb 21, 2023 |
NBN | 8 | Sep 1, 2022 |
PALB2 | 8 | Feb 21, 2023 |
PMS2 | 1 | Sep 1, 2022 |
POLD1 | 1 | May 11, 2021 |
PTEN | 2 | Feb 21, 2023 |
RAD50 | 8 | Sep 1, 2022 |
RAD51C | 7 | Feb 21, 2023 |
RAD51D | 7 | Jun 13, 2019 |
RAD51L3-RFFL | 7 | Jun 13, 2019 |
RET | 1 | Sep 1, 2022 |
TP53 | 5 | May 11, 2021 |
Condition
Name | Submissions | Last Updated |
---|---|---|
Breast and/or ovarian cancer | 168 | Jun 13, 2019 |
Carcinoma of pancreas | 29 | May 11, 2021 |
Endometrial carcinoma | 32 | Feb 21, 2023 |
Hepatocellular carcinoma | 7 | Sep 1, 2022 |
Uterine corpus cancer | 15 | Feb 21, 2023 |